Previous 10 | Next 10 |
Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024, respectively; Additional Phase 2 data expected in 2024 Alignment on de...
2023-12-13 04:50:52 ET Summary Mereo BioPharma has shifted its focus from developing anti-TIGIT molecules to rare disease programs. The company's current pipeline includes programs for Osteogenesis Imperfecta, Alpha-1 Antitrypsin Deficiency-associated Lung Disease, and anti-TIGIT ...
2023-11-14 21:51:36 ET Summary Ultragenyx shows clinical innovation in rare diseases; financial growth is offset by high net loss and cash burn. Recent earnings indicate YOY revenue growth but a substantial net loss; operating expenses have decreased. Ultragenyx's liquid asset...
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on recent program developments and third quarter 2023 financial ...
2023-10-23 08:21:00 ET Textainer Group Holdings ( TGH ) +43% . Mynaric ( MYNA ) +17% . Navios Maritime Holdings ( NM ) +17% to buy N Logistics in $2.28/share all-cash deal. Next. ( EGOX ) +16% . Harpoon Therapeutics ( HARP ) ...
2023-10-16 13:36:37 ET Gainers: Tempest Therapeutics ( TPST ) +98% . Momentus ( MNTS ) +51% . PCTEL ( PCTI ) +47% . Almacenes Exito ( EXTO ) +33% . Mereo Biopharma Group Plc ( MREO ) +30% . Rani Therapeutics Holdings ( RANI...
2023-10-16 12:17:55 ET DENVER, Colo., Oct. 16, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Processa Pharmaceuticals Inc (NASDAQ: PCSA), Mereo BioPharma Group PLC (NASDAQ: MREO), Tempest Therape...
2023-10-16 10:00:00 ET More on Health Care Select Sector SPDR Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further...
2023-10-16 09:56:56 ET DENVER, Colo., Oct. 16, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; LQR House Inc (NASDAQ: LQR), Better Therapeutics Inc (NASDAQ: BTTX), Mereo BioPharma Group PLC (NASDAQ: MREO)...
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate associated with continuous and meaningful improvements in bone mineral density (BMD) Ultragenyx hosting Analyst Day on Monday, October 16 at 8:30 a.m. ET NOVATO, Cal...
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutica...
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate ...
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $6.00 for MREO on 2024-03-28 07:08:00. The adjusted price target was set to $6.00. At the time of the announcement, MREO was trading at $3. The overall price target consensus is at $4.00 with high pric...